Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, a First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Monte Rosa Therapeutics, Inc. announced a novel development candidate, MRT-8102. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β and the NLRP3 inflammasome, which are critical elements of the inflammatory process.